Last updated: September 23, 2022
Sponsor: PT. Prodia Stem Cell Indonesia
Overall Status: Active - Recruiting
Phase
1/2
Condition
Diabetes Prevention
Diabetes And Hypertension
Hormone Deficiencies
Treatment
N/AClinical Study ID
NCT05279768
CT/PCOS/PSI/2022
Ages 20-40 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- PCOS patients with insulin resistance based on Rotterdam Consensus criteria, i.e.menstrual disorders (oligomenorhea/ amennorhea)
- Patients must have hiperandrogenemia clinical and laboratory proof (Ferriman Gallweyscore >8)
- Patients with Free Androgen Index (FAI) >4 and ovary polycystic from USG transvaginal
- Patients with Homeostatic (HOMA) IR score ≥ 1.7
Exclusion
Exclusion Criteria:
- Patients who are allergic to component of WJ-MSC or Secretome.
- Patients who are not currently on hormon treatment of other resistance treatment.
- Refusing or not participating in part / all of the research process.
- Patients with positive diagnosis of hepatitis A,B,C, and HIV
Study Design
Total Participants: 40
Study Start date:
September 01, 2022
Estimated Completion Date:
December 31, 2023
Study Description
Connect with a study center
PT Prodia StemCell Indonesia
Jakarta,
IndonesiaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.